Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Study on Preventing HPV Transmission among Gay and Bi-sexual Men Through Use of Divine 9 Personal Lubricant Launches at McGill University
  • USA - English


News provided by

CarraShield Labs, Inc.

May 16, 2016, 04:00 ET

Share this article

Share toX

Share this article

Share toX

McGill University
McGill University

Potentially, the carrageenan-based lubricant (Divine 9 with CarraShield) can provide total protection from HPV.

Post this

Orlando, Florida (PRWEB) May 16, 2016 -- CarraShield Labs, Inc. announced today that McGill University Medical School’s Division of Cancer Epidemiology has launched a large-scale study on the ability of Divine 9® personal lubricant, made with CarraShield®, to block the transmission of HPV in gay and bi-sexual men. HPV is a serious health risk for the gay and bi-sexual community as it causes throat, anal and penile cancers as well as genital warts. CarraShield Labs’ proprietary CarraShield formula contains a unique type of carrageenan, a natural seaweed extract that has been shown in previous in vitro (laboratory) and in vivo (animal) studies conducted by the National Cancer Institute to act as an HPV blocking agent.

The new McGill study is called "LIMIT-HPV," an acronym for Lubricant Investigation in Men to Inhibit Transmission of HPV. The LIMIT-HPV study will involve tracking the presence of HPV infections in over three hundred male volunteers for a one year period. As with McGill University’s earlier CATCH study investigating the ability of CarraShield to prevent HPV infections in women, the LIMIT-HPV research will focus on determining the protective capabilities of CarraShield in the Divine 9 lubricant as compared to a placebo lubricant using a double blind procedure. Participants are instructed to use the lubricant as they normally would in an intimate encounter. Earlier research suggests the CarraShield in Divine 9 creates a protective barrier that traps the virus and thereby prevents infection.

The leader of the research team is Dr. Eduardo Franco, Director of the Division of Cancer Epidemiology. He is conducting this study in collaboration with colleagues at McGill and at University of Montreal. Professor Franco's research during the last 30 years has focused on molecular epidemiology and prevention of cervical cancer and human papillomavirus-associated diseases, Dr. Franco has published more than 400 scientific articles and edited two books on cancer epidemiology and prevention.

“Many participants are being solicited at Montreal’s four major universities: McGill, Concordia, UQAM and the Université de Montréal, as well as at some inner-city clinics.” stated Dr. Franco. “We will be splitting the men into two groups, about 110 at HIV clinics who are already HIV-positive and 270 men who are not, to be able to test the hypothesis of a reasonable protective effect,” he says. “Health Canada has already approved this study. Most of the complicated steps were completed with the first study — the female study — and we are delighted to have received joint funding from the Canadian Institutes of Health Research and the Canadian Cancer Society. CarraShield Labs has provided us the Divine 9 and the placebo in unmarked packaging so that no one knows which is which.”

“While the HPV vaccine Gardasil protects against only four strains of the virus,” Dr. Franco went on to say, “potentially, the carrageenan-based lubricant can provide total protection from HPV.”

A U.S. Centers for Disease Control fact sheet on HPV states, “HPV, the most common sexually transmitted disease in the United States, is also a concern for gay, bisexual, and other men who have sex with men. Some types of HPV can cause genital and anal warts and some can lead to the development of anal and oral cancers. Gay, bisexual, and other men who have sex with men are 17 times more likely to get anal cancer than heterosexual men.”

“LIMIT-HPV is the first and only study on preventing HPV infection in gay and bi-sexual men using a protective barrier lubricant, in spite of the fact this community is reported to have the highest HPV infection rates of any single social group.” said Dean Fresonke, CEO of CarraShield Labs. “We look forward to supporting Dr. Franco and his research team and hope the CarraShield in Divine 9 can help win the fight against HPV-induced cancers in the gay community around the world.”

About CarraShield Labs, Inc.
CarraShield Labs is dedicated to improving sexual wellness. Intensive research has led to a line of products formulated with the company’s proprietary sea algae-based formula called CarraShield®. CarraShield is showing promise in its ability to block HPV infection in government-funded, independent laboratory studies. In addition to potential health benefits, Divine 9 provides a silky skin-on-skin sensation for the ultimate sensual experience. Look for Divine 9 personal lubricants in select retailers and on discriminating websites. Divine 9 with CarraShield is “The Ultimate in Pleasure & Protection”®. Learn more at http://www.carrashieldlabs.com.

Jeff Hawkins, CarraShield Labs, Inc., http://www.carrashieldlabs.com, +1 (310) 720-0215, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.